159 related articles for article (PubMed ID: 35253343)
21. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
22. The genetics of vascular birthmarks.
Mahajan P; Bergstrom KL; Phung TL; Metry DW
Clin Dermatol; 2022; 40(4):313-321. PubMed ID: 35181412
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
24. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
25. Molecular changes associated with vascular malformations.
Fereydooni A; Dardik A; Nassiri N
J Vasc Surg; 2019 Jul; 70(1):314-326.e1. PubMed ID: 30922748
[TBL] [Abstract][Full Text] [Related]
26. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
27. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
28. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
29. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation.
Da Costa R; De Almeida S; Chevarin M; Hadj-Rabia S; Leclerc-Mercier S; Thauvin-Robinet C; Garrido C; Faivre L; Vabres P; Duplomb L; Jego G
Biochem Biophys Res Commun; 2020 Sep; 530(3):520-526. PubMed ID: 32620236
[TBL] [Abstract][Full Text] [Related]
30. Somatic TEK variant with intraarticular venous malformation and knee hemarthrosis treated with rapamycin.
Adham S; Revencu N; Mestre S; Nou-Howaldt M; Vernhet-Kovacsik H; Quéré I
Mol Genet Genomic Med; 2022 Jun; 10(6):e1931. PubMed ID: 35426265
[TBL] [Abstract][Full Text] [Related]
31. Cell Populations Expressing Stemness-Associated Markers in Vascular Anomalies.
Kilmister EJ; Hansen L; Davis PF; Hall SRR; Tan ST
Front Surg; 2020; 7():610758. PubMed ID: 33634164
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus for the treatment of children with various complicated vascular anomalies.
Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
[TBL] [Abstract][Full Text] [Related]
33. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
34. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
35. Genetic Causes of Vascular Malformations and Common Signaling Pathways Involved in Their Formation.
Rose AL; Cathey SS
Dermatol Clin; 2022 Oct; 40(4):449-459. PubMed ID: 36243432
[TBL] [Abstract][Full Text] [Related]
36. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
[TBL] [Abstract][Full Text] [Related]
37. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
Seront E; Van Damme A; Legrand C; Bisdorff-Bresson A; Orcel P; Funck-Brentano T; Sevestre MA; Dompmartin A; Quere I; Brouillard P; Revencu N; De Bortoli M; Hammer F; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937645
[TBL] [Abstract][Full Text] [Related]
38. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
39. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
